Partnering

Partnering

Betagenon is actively seeking partners for it’s clinical AMPK activator program.

Betagenon’s preclinical and clinical results support the development of it’s portfolio of AMPK activator compounds, including O304, as a treatment for Type 2 Diabetes, Heart Failure with preserved Ejection Fraction (HFpEF), Diabetic/Chronic Kidney Disease, Inflammatory Conditions as well as for certain Cancers. Betagenon is currently seeking partners for the continued clinical development of it’s AMPK activator program in these multiple indications.